Merck reported Phase 3 results for sacituzumab tirumotecan (sacituzumab tirumotecan, sac-TMT), describing a reduction in the risk of death by one-third in advanced endometrial cancer. The readout, presented in the context of multiple global studies, is positioned as part of Merck’s strategy to replace future revenue tied to Keytruda patent expiry. Merck is running 18 global Phase 3 trials of sac-TMT, including multiple women’s cancer programs, and the company is using the endometrial data to support expansion of regulatory filings outside China where the drug is already approved. For oncology developers, the trial provides another datapoint for the ADC’s ongoing clinical momentum and for how companies are repositioning pipeline priorities around next-generation targeted cytotoxic platforms.